FDA cleared and CLIA-waived Diasorin’s Liaison Nes multiplex group A streptococcus rapid molecular test on the firm’s point-of-care PCR instrument. Diasorin said the assay returns results in about 15 minutes with minimal hands-on time and that reagents can be stored at room temperature. The clearance builds on prior FDA action for the Liaison Nes respiratory panel for influenza A and B, RSV, and COVID-19, which already includes a CLIA waiver. Diasorin framed the additional assay as part of expanding the Nes menu for high-impact infectious diseases in outpatient and decentralized settings. Company disclosures tie the platform buildout to commercial targets, noting executives described plans for Nes to generate more than $150 million in U.S. revenue by 2030. A GI panel on Liaison Plex was also cleared in May, according to the announcement.